Rational development of Stafib-2: a selective, nanomolar inhibitor of the transcription factor STAT5b

The transcription factor STAT5b is a target for tumour therapy. We recently reported catechol bisphosphate and derivatives such as Stafib-1 as the first selective inhibitors of the STAT5b SH2 domain. Here, we demonstrate STAT5b binding of catechol bisphosphate by solid-state nuclear magnetic resonan...

Descripción completa

Detalles Bibliográficos
Autores principales: Elumalai, Nagarajan, Berg, Angela, Rubner, Stefan, Blechschmidt, Linda, Song, Chen, Natarajan, Kalaiselvi, Matysik, Jörg, Berg, Thorsten
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5429769/
https://www.ncbi.nlm.nih.gov/pubmed/28400581
http://dx.doi.org/10.1038/s41598-017-00920-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5429769/
https://www.ncbi.nlm.nih.gov/pubmed/28400581
http://dx.doi.org/10.1038/s41598-017-00920-3

Ejemplares similares